Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization.

Wojnarowicz PM, Lima E Silva R, Ohnaka M, Lee SB, Chin Y, Kulukian A, Chang SH, Desai B, Garcia Escolano M, Shah R, Garcia-Cao M, Xu S, Kadam R, Goldgur Y, Miller MA, Ouerfelli O, Yang G, Arakawa T, Albanese SK, Garland WA, Stoller G, Chaudhary J, Norton L, Soni RK, Philip J, Hendrickson RC, Iavarone A, Dannenberg AJ, Chodera JD, Pavletich N, Lasorella A, Campochiaro PA, Benezra R.

Cell Rep. 2019 Oct 1;29(1):62-75.e7. doi: 10.1016/j.celrep.2019.08.073.

2.

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.

Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, Rumandla A, Gurrapu S, Chakraborty G, Su J, Yang G, Liang X, Wang G, Rosen N, Scher HI, Ouerfelli O, Giancotti FG.

Cancer Cell. 2019 Aug 12;36(2):139-155.e10. doi: 10.1016/j.ccell.2019.06.009. Epub 2019 Jul 18.

PMID:
31327655
3.

CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA4 Cleavage with ApA>p Formation Terminating RNase Activity.

Jia N, Jones R, Yang G, Ouerfelli O, Patel DJ.

Mol Cell. 2019 Sep 5;75(5):944-956.e6. doi: 10.1016/j.molcel.2019.06.014. Epub 2019 Jul 17.

PMID:
31326273
4.

Structure and mechanism of pyrimidine-pyrimidone (6-4) photoproduct recognition by the Rad4/XPC nucleotide excision repair complex.

Paul D, Mu H, Zhao H, Ouerfelli O, Jeffrey PD, Broyde S, Min JH.

Nucleic Acids Res. 2019 Jul 9;47(12):6015-6028. doi: 10.1093/nar/gkz359.

5.

Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition.

Ballinger E, Mosior J, Hartman T, Burns-Huang K, Gold B, Morris R, Goullieux L, Blanc I, Vaubourgeix J, Lagrange S, Fraisse L, Sans S, Couturier C, Bacqué E, Rhee K, Scarry SM, Aubé J, Yang G, Ouerfelli O, Schnappinger D, Ioerger TR, Engelhart CA, McConnell JA, McAulay K, Fay A, Roubert C, Sacchettini J, Nathan C.

Science. 2019 Feb 1;363(6426). pii: eaau8959. doi: 10.1126/science.aau8959. Erratum in: Science. 2019 Jun 21;364(6446):.

6.

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A.

Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055.

7.

Targetable Clinical Nanoparticles for Precision Cancer Therapy Based on Disease-Specific Molecular Inflection Points.

Kaittanis C, Bolaender A, Yoo B, Shah N, Ouerfelli O, Grimm J.

Nano Lett. 2017 Nov 8;17(11):7160-7168. doi: 10.1021/acs.nanolett.7b04209. Epub 2017 Oct 23.

8.

Distinct Spatiotemporal Dynamics of Peptidoglycan Synthesis between Mycobacterium smegmatis and Mycobacterium tuberculosis.

Botella H, Yang G, Ouerfelli O, Ehrt S, Nathan CF, Vaubourgeix J.

MBio. 2017 Sep 12;8(5). pii: e01183-17. doi: 10.1128/mBio.01183-17.

9.

Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer.

Zarbo A, Ouerfelli O, Klang M, Lacouture ME.

JAMA Dermatol. 2016 Sep 1;152(9):1054-5. doi: 10.1001/jamadermatol.2016.2665. No abstract available.

PMID:
27486908
10.

Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status".

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL.

Nat Med. 2016 Jun 7;22(6):578-9. doi: 10.1038/nm.4094. No abstract available.

PMID:
27270773
11.

Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors.

Shukla N, Somwar R, Smith RS, Ambati S, Munoz S, Merchant M, D'Arcy P, Wang X, Kobos R, Antczak C, Bhinder B, Shum D, Radu C, Yang G, Taylor BS, Ng CK, Weigelt B, Khodos I, de Stanchina E, Reis-Filho JS, Ouerfelli O, Linder S, Djaballah H, Ladanyi M.

Cancer Res. 2016 Aug 1;76(15):4525-34. doi: 10.1158/0008-5472.CAN-16-1040. Epub 2016 Jun 2.

12.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

13.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

14.

Loss of BAP1 function leads to EZH2-dependent transformation.

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL.

Nat Med. 2015 Nov;21(11):1344-9. doi: 10.1038/nm.3947. Epub 2015 Oct 5.

15.

Human Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1.

Eller CH, Chao TY, Singarapu KK, Ouerfelli O, Yang G, Markley JL, Danishefsky SJ, Raines RT.

ACS Cent Sci. 2015 Jul 22;1(4):181-190. Epub 2015 Jul 13.

16.

Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells.

Vaubourgeix J, Lin G, Dhar N, Chenouard N, Jiang X, Botella H, Lupoli T, Mariani O, Yang G, Ouerfelli O, Unser M, Schnappinger D, McKinney J, Nathan C.

Cell Host Microbe. 2015 Feb 11;17(2):178-90. doi: 10.1016/j.chom.2014.12.008. Epub 2015 Jan 22.

17.

DNA repair. Mechanism of DNA interstrand cross-link processing by repair nuclease FAN1.

Wang R, Persky NS, Yoo B, Ouerfelli O, Smogorzewska A, Elledge SJ, Pavletich NP.

Science. 2014 Nov 28;346(6213):1127-30. doi: 10.1126/science.1258973.

18.

Affinity of monoclonal antibodies for Globo-series glycans.

Eller CH, Yang G, Ouerfelli O, Raines RT.

Carbohydr Res. 2014 Oct 9;397:1-6. doi: 10.1016/j.carres.2014.07.003. Epub 2014 Jul 14.

19.

Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.

Cheal SM, Yoo B, Boughdad S, Punzalan B, Yang G, Dilhas A, Torchon G, Pu J, Axworthy DB, Zanzonico P, Ouerfelli O, Larson SM.

Mol Pharm. 2014 Feb 3;11(2):400-16. doi: 10.1021/mp4003128. Epub 2013 Nov 23.

20.

N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein.

Yoo B, Cheal SM, Torchon G, Dilhas A, Yang G, Pu J, Punzalan B, Larson SM, Ouerfelli O.

Bioconjug Chem. 2013 Dec 18;24(12):2088-103. doi: 10.1021/bc400333m. Epub 2013 Nov 18.

21.

Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling.

Petrova E, Rios-Esteves J, Ouerfelli O, Glickman JF, Resh MD.

Nat Chem Biol. 2013 Apr;9(4):247-9. doi: 10.1038/nchembio.1184. Epub 2013 Feb 17.

22.

Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials.

Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11. doi: 10.1073/pnas.1214188109. Epub 2012 Sep 10.

23.

ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.

24.

Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.

Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ, Djaballah H, Varmus HE.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16375-80. doi: 10.1073/pnas.1113554108. Epub 2011 Sep 19.

25.

Emergence of potent inhibitors of metastasis in lung cancer via syntheses based on migrastatin.

Lecomte N, Njardarson JT, Nagorny P, Yang G, Downey R, Ouerfelli O, Moore MA, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15074-8. doi: 10.1073/pnas.1015247108. Epub 2011 Aug 1.

26.

Radiosynthesis of the tumor hypoxia marker [18F]TFMISO via O-[18F]trifluoroethylation reveals a striking difference between trifluoroethyl tosylate and iodide in regiochemical reactivity toward oxygen nucleophiles.

Suehiro M, Yang G, Torchon G, Ackerstaff E, Humm J, Koutcher J, Ouerfelli O.

Bioorg Med Chem. 2011 Apr 1;19(7):2287-97. doi: 10.1016/j.bmc.2011.02.026. Epub 2011 Feb 18.

27.

A protecting group-free synthesis of deazathiamine: a step toward inhibitor design.

Zhao H, de Carvalho LP, Nathan C, Ouerfelli O.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6472-4. doi: 10.1016/j.bmcl.2010.09.053. Epub 2010 Sep 16.

28.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL.

J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.

29.

Inhibition of human peptide deformylase disrupts mitochondrial function.

Escobar-Alvarez S, Gardner J, Sheth A, Manfredi G, Yang G, Ouerfelli O, Heaney ML, Scheinberg DA.

Mol Cell Biol. 2010 Nov;30(21):5099-109. doi: 10.1128/MCB.00469-10. Epub 2010 Aug 30.

30.

Confirmation of the Structures of Synthetic Derivatives of Migrastatin in the Light of Recently Disclosed Crystallographically Based Claims.

Nagorny P, Krauss I, Njardarson JT, Perez L, Gaul C, Yang G, Ouerfelli O, Danishefsky SJ.

Tetrahedron Lett. 2010 Jul 28;51(30):3873-3875.

31.

Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase.

de Carvalho LP, Zhao H, Dickinson CE, Arango NM, Lima CD, Fischer SM, Ouerfelli O, Nathan C, Rhee KY.

Chem Biol. 2010 Apr 23;17(4):323-32. doi: 10.1016/j.chembiol.2010.03.009.

32.

Diverted total synthesis leads to the generation of promising cell-migration inhibitors for treatment of tumor metastasis: in vivo and mechanistic studies on the migrastatin core ether analog.

Oskarsson T, Nagorny P, Krauss IJ, Perez L, Mandal M, Yang G, Ouerfelli O, Xiao D, Moore MA, Massagué J, Danishefsky SJ.

J Am Chem Soc. 2010 Mar 10;132(9):3224-8. doi: 10.1021/ja9101503.

33.

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W.

J Clin Invest. 2009 Oct;119(10):3000-10. doi: 10.1172/JCI38746. Epub 2009 Sep 14.

34.

Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?

Suehiro M, Burgman P, Carlin S, Burke S, Yang G, Ouerfelli O, Oehler-Janne C, O'Donoghue J, Ling C, Humm J.

Nucl Med Biol. 2009 Jul;36(5):477-87. doi: 10.1016/j.nucmedbio.2009.03.002. Epub 2009 May 7.

35.

From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.

Zhu J, Wan Q, Lee D, Yang G, Spassova MK, Ouerfelli O, Ragupathi G, Damani P, Livingston PO, Danishefsky SJ.

J Am Chem Soc. 2009 Jul 8;131(26):9298-303. doi: 10.1021/ja901415s.

36.

Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells.

La Rocca R, Fulciniti M, Lakshmikanth T, Mesuraca M, Ali TH, Mazzei V, Amodio N, Catalano L, Rotoli B, Ouerfelli O, Grieco M, Gulletta E, Bond HM, Morrone G, Ferrone S, Carbone E.

J Immunol. 2009 Apr 15;182(8):4529-37. doi: 10.4049/jimmunol.0802109.

37.

Synthesis of Human Cancer Associated Globo-H (MBr1) Glycosylamino Acid: Some Mechanistic and Conformational Reinvestigations.

Zhu J, Wan Q, Yang G, Ouerfelli O, Danishefsky SJ.

Heterocycles. 2009 Apr 1;79(1):441-449.

38.

Structure and activity of human mitochondrial peptide deformylase, a novel cancer target.

Escobar-Alvarez S, Goldgur Y, Yang G, Ouerfelli O, Li Y, Scheinberg DA.

J Mol Biol. 2009 Apr 17;387(5):1211-28. doi: 10.1016/j.jmb.2009.02.032. Epub 2009 Feb 21.

39.

Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays.

Maretzky T, Yang G, Ouerfelli O, Overall CM, Worpenberg S, Hassiepen U, Eder J, Blobel CP.

Biochem J. 2009 Apr 28;420(1):105-13. doi: 10.1042/BJ20082127.

PMID:
19207106
40.

Stereo-controlled synthesis of novel photoreactive gamma-secretase inhibitors.

Yang G, Yin YI, Chun J, Shelton CC, Ouerfelli O, Li YM.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):922-5. doi: 10.1016/j.bmcl.2008.11.117. Epub 2008 Dec 7.

41.

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.

Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO.

Clin Cancer Res. 2007 Jul 15;13(14):4170-7.

42.

High-throughput identification of inhibitors of human mitochondrial peptide deformylase.

Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, Wu N, Yang G, Ouerfelli O, Li YM, Scheinberg DA, Djaballah H.

J Biomol Screen. 2007 Jun;12(4):521-35. Epub 2007 Apr 13.

43.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2006 Nov 1;12(21):6494-501.

44.

A peptidomimetic siRNA transfection reagent for highly effective gene silencing.

Utku Y, Dehan E, Ouerfelli O, Piano F, Zuckermann RN, Pagano M, Kirshenbaum K.

Mol Biosyst. 2006 Jun;2(6-7):312-7. Epub 2006 May 17.

PMID:
16880950
45.

Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.

Ragupathi G, Koide F, Livingston PO, Cho YS, Endo A, Wan Q, Spassova MK, Keding SJ, Allen J, Ouerfelli O, Wilson RM, Danishefsky SJ.

J Am Chem Soc. 2006 Mar 1;128(8):2715-25.

PMID:
16492059
46.

Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities.

Ouerfelli O, Warren JD, Wilson RM, Danishefsky SJ.

Expert Rev Vaccines. 2005 Oct;4(5):677-85. Review.

PMID:
16221069
47.

Sequence characteristics of functional siRNAs.

Jagla B, Aulner N, Kelly PD, Song D, Volchuk A, Zatorski A, Shum D, Mayer T, De Angelis DA, Ouerfelli O, Rutishauser U, Rothman JE.

RNA. 2005 Jun;11(6):864-72.

48.

Chemical inhibition of N-WASP by stabilization of a native autoinhibited conformation.

Peterson JR, Bickford LC, Morgan D, Kim AS, Ouerfelli O, Kirschner MW, Rosen MK.

Nat Struct Mol Biol. 2004 Aug;11(8):747-55. Epub 2004 Jul 4.

PMID:
15235593
49.

Structure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' protein.

Abdul-Manan N, Aghazadeh B, Liu GA, Majumdar A, Ouerfelli O, Siminovitch KA, Rosen MK.

Nature. 1999 May 27;399(6734):379-83.

PMID:
10360578
50.

Supplemental Content

Loading ...
Support Center